Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Just For You
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Author: Jeffrey Neal Johnson. Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring.
If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture. Read Addison Wiggin's full breakdown of the real Iran story
Abbott Laboratories' stock price recently touched a 52-week low, closing just above $100 in the last trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories' situation reveals a potential disconnect between market sentiment and operational reality, raising a critical question: Is the market's pessimism justified, or has a significant value opportunity emerged for long-term investors? Separating the Signal From the NoiseA stock like Abbott does not fall without reason. Its recent decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories' fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in that division, primarily due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been upfront about the challenge and outlined a plan to turn it around: price and promotion initiatives plus a pipeline of at least eight new product launches in 2026 aimed at reigniting volume growth, with management forecasting a return to growth in the second half of the year. The second factor is external and broader in scope. The market has been experiencing a notable rotation of capital. In periods of economic optimism, investors often move funds away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. That broad trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment works toward a short-term recovery, Abbott Laboratories' core businesses remain robust, led by its largest and most profitable division: Medical Devices. This segment is accelerating, posting 10.4% organic growth in the most recent quarter. The company's diversified model provides a strong counterbalance to the isolated weakness in Nutrition, and the true health of the business is most evident in these high-performing areas.
Medical Devices: The Medical Devices engine is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a major growth driver. This product line, which lets users track glucose levels without routine fingersticks, generated over $7.5 billion in sales in 2025 and is central to Abbott Laboratories' sustained success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. That performance reflects a portfolio of best-in-class products—such as MitraClip and TriClip, which offer minimally invasive solutions for valve repair—and a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning itself for future growth through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. This deal would immediately position Abbott as a leader in the rapidly expanding, multi-billion-dollar market for cancer diagnostics, adding a high-growth vertical that could become a meaningful contributor to revenue for years to come. That bullish outlook is shared by many professional analysts. Wall Street maintains a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying more than 30% upside from current levels and reflecting a widespread view that the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors, especially those focused on building a reliable income stream, Abbott's dividend is a standout feature. Abbott Laboratories is a member of the S&P 500 Dividend Kings, a group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a strong commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott's stock price has a direct benefit for new investors: a higher dividend yield. At current levels, Abbott offers a yield of about 2.5%, allowing investors to lock in a relatively higher rate of income from a historically reliable payer. The dividend appears secure: Abbott Laboratories' payout ratio is about 68% of earnings and represents roughly 37% of cash flow, indicating the company generates more than enough cash to cover distributions with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott Laboratories appears disconnected from the company's business reality. Temporary headwinds in a single division and a broad market rotation have depressed the stock price, yet Abbott's fundamental growth engines are accelerating. Its dominant Medical Devices division continues to deliver, the dividend remains a bedrock of reliability, and strategic catalysts like the Exact Sciences acquisition could add a significant growth vertical. For investors with a long-term horizon, the current valuation suggests a noteworthy gap between market price and fundamental value—an opportunity that deserves serious consideration. |
